KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

Molecular Oncology - Tập 9 - Trang 1434-1446 - 2015
Dominic Leiser1, Michaela Medová1, Kei Mikami1, Lluís Nisa1, Deborah Stroka2, Andree Blaukat3, Friedhelm Bladt3, Daniel M. Aebersold1, Yitzhak Zimmer1
1Department of Radiation Oncology, Department of Clinical Research, Inselspital, Bern University Hospital, and University of Bern, Switzerland
2Department of Visceral Surgery, Department of Clinical Research, Inselspital, Bern University Hospital, and University of Bern, Switzerland
3Merck Serono an Affiliate of Merck Serono Research & Development, Merck KGaA, 64271 Darmstadt, Germany

Tóm tắt

The MET receptor tyrosine kinase is often deregulated in human cancers and several MET inhibitors are evaluated in clinical trials. Similarly to EGFR, MET signals through the RAS‐RAF‐ERK/MAPK pathway which plays key roles in cell proliferation and survival. Mutations of genes encoding for RAS proteins, particularly in KRAS, are commonly found in various tumors and are associated with constitutive activation of the MAPK pathway. It was shown for EGFR, that KRAS mutations render upstream EGFR inhibition ineffective in EGFR‐positive colorectal cancers. Currently, there are no clinical studies evaluating MET inhibition impairment due to RAS mutations. To test the impact of RAS mutations on MET targeting, we generated tumor cells responsive to the MET inhibitor EMD1214063 that express KRAS G12V, G12D, G13D and HRAS G12V variants. We demonstrate that these MAPK‐activating RAS mutations differentially interfere with MET‐mediated biological effects of MET inhibition. We report increased residual ERK1/2 phosphorylation indicating that the downstream pathway remains active in presence of MET inhibition. Consequently, RAS variants counteracted MET inhibition‐induced morphological changes as well as anti‐proliferative and anchorage‐independent growth effects. The effect of RAS mutants was reversed when MET inhibition was combined with MEK inhibitors AZD6244 and UO126. In an in vivo mouse xenograft model, MET‐driven tumors harboring mutated RAS displayed resistance to MET inhibition. Taken together, our results demonstrate for the first time in details the role of KRAS and HRAS mutations in resistance to MET inhibition and suggest targeting both MET and MEK as an effective strategy when both oncogenic drivers are expressed.

Tài liệu tham khảo

10.1200/JCO.2007.14.7116 10.4155/fmc.11.121 10.1158/1078-0432.CCR-12-3459 10.1038/sj.onc.1207691 10.1158/1078-0432.CCR-12-3247 10.1074/jbc.270.17.9809 10.1158/0008-5472.CAN-10-0436 10.1136/jclinpath-2013-201663 Christensen J.G., 2003, A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo, Cancer Res., 63, 7345 10.1186/1471-2407-9-411 10.1056/NEJMoa1305275 10.4161/sgtp.26905 10.1016/j.coph.2013.05.018 Graham K.A., 1985, Varying degrees of amplification of the N-ras oncogene in the human breast cancer cell line MCF-7, Cancer Res., 45, 2201 10.1101/cshperspect.a009209 10.1097/PPO.0b013e31829e3c9a 10.1038/bjc.1986.47 10.1016/j.ceb.2008.12.010 10.1073/pnas.94.21.11445 Karnoub A.E., 2008, Ras oncogenes: split personalities. Nature reviews, Mol. Cel. Biol., 9, 517 10.1158/0008-5472.CAN-12-3256 10.1128/MCB.16.7.3923 10.1016/j.copbio.2011.10.004 10.1200/JCO.2007.12.5906 Long I.S., 2003, Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo, Mol. Cancer Res., 1, 393 Mattingly R.R., 2013, Activated ras as a therapeutic target: constraints on directly targeting ras isoforms and wild-type versus mutated proteins, ISRN Oncol., 2013, 536529 10.1158/1535-7163.MCT-13-0151 Michieli P., 2013, Targeted therapies: tivantinib–a cytotoxic drug in MET inhibitor's clothes? Nature reviews, Clin. Oncol., 10, 372 10.1007/s00432-013-1401-9 10.1097/JTO.0b013e3181d0a4db 10.1097/JTO.0b013e3181913e0e Pylayeva-Gupta Y., 2011, RAS oncogenes: weaving a tumorigenic web. Nature reviews, Cancer, 11, 761 10.1007/82_2010_68 10.1016/j.cllc.2012.01.003 10.1016/j.ctrv.2013.02.001 10.1038/312071a0 10.1158/1078-0432.CCR-06-0096 10.1093/jnci/djp280 10.1517/14728222.2013.764990 10.1002/j.1460-2075.1984.tb02236.x 10.1038/bjc.2012.129 10.1021/bi4007644 10.3109/01902148.2013.819535 10.1089/thy.2013.0621 10.1158/1535-7163.MCT-13-0187 10.1016/j.canlet.2009.08.017
Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 9

1434-1446

Thông tin tác giả